Lapatinib (GW572016) oral tablets

DRUG2 trials

Sponsors

GlaxoSmithKline, Novartis Pharmaceuticals

Conditions

AdenocarcinomaNeoplasms, Breast

Phase 2

Effects Of Lapatinib (GW572016) In Patients With Relapsed Adenocarcinoma Of The Esophagus

CompletedNCT00259987

GlaxoSmithKlineAdenocarcinoma

Start: 2005-11-30End: 2007-05-31Updated: 2009-05-18

Phase 3

Study In Women And Men With Metastatic Breast Cancer That Have Overexpression Of ErbB2

CompletedNCT00281658

Novartis PharmaceuticalsNeoplasms, Breast

Start: 2006-01-02End: 2021-11-23Updated: 2023-02-10

Related Papers

Association of phosphatase and tensin homolog low and phosphatidylinositol 3-kinase catalytic subunit alpha gene mutations on outcome in human epidermal growth factor receptor 2-positive metastatic breast cancer patients treated with first-line lapatinib plus paclitaxel or paclitaxel alone.

2014-07-2426 citations

Evaluation of pro-apoptotic BIM gene loss of function on lapatinib efficacy in patients with metastatic breast cancer (MBC) and in HER2-amplified cell lines.

Journal of Clinical Oncology2014-05-20